TScan Therapeutics, Inc.

NasdaqGM:TCRX Stock Report

Market Cap: US$60.0m

TScan Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

TScan Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.4%

Buyback Yield

Total Shareholder Yield-0.4%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Mar 07

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Summary Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barring positive feedback from regulatory authorities, the company hopes to develop TSC-101 for AML, MDS, ALL patients who undergo HSCT in a pivotal study in the 2nd half of 2025. The company is developing multiplex TCR-Ts for treatment of patients with solid tumors, with phase 1 PLEXI-T trial data anticipated in the second half of 2025. Financially stable with $290.1 million in cash, TScan Therapeutics has secured a non-dilutive loan and a $30 million direct offering. Read the full article on Seeking Alpha
Seeking Alpha • Feb 10

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Summary TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism. TCRX's potential approval for TSC-101 could tap a $100-$200 million market, making the current valuation a bargain despite inherent risks. Read the full article on Seeking Alpha
Analysis Article • Nov 06

Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Aug 26

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Summary TScan Therapeutics focuses on TCR-T therapies for cancer and autoimmune diseases, leveraging its ImmunoBank and proprietary ReceptorScan platform. TCRX’s pipeline is in the early clinical stages, with multiple near-term catalysts, including promising regulatory designations and potential partnerships. The company’s leading candidates, TSC-100 and TSC-101, target AML, MDS, and ALL, with FDA RMAT designation potentially expediting approval. TCRX seems well-capitalized, with a strong balance sheet and a cash runway of 4 years. It also appears undervalued relative to its peers. Despite its early-stage research, I believe TCRX’s innovative technology and near-term catalysts make it a speculative "buy." Read the full article on Seeking Alpha
Analysis Article • Mar 23

Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

It's not a stretch to say that TScan Therapeutics, Inc.'s ( NASDAQ:TCRX ) price-to-sales (or "P/S") ratio of 18.2x...
Analysis Article • Feb 17

Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Mar 11

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

TScan Therapeutics, Inc. ( NASDAQ:TCRX ) just released its latest yearly report and things are not looking great...
Seeking Alpha • Aug 10

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

TScan Therapeutics press release (NASDAQ:TCRX): Q2 GAAP EPS of -$0.63 beats by $0.13. Revenue of $4.05M (+42.6% Y/Y) beats by $1.05M.
Seeking Alpha • Jul 07

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

TScan Therapeutics (NASDAQ:TCRX) has appointed Dr. Debora Barton,  as Chief Medical Officer.  Most recently, Dr. Barton was the Chief Medical Officer at Carisma Therapeutics.  In May, TScan got FDA nod to start trial of TSC-101 in blood cancer patients undergoing cell transplant.
Analysis Article • May 22

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jan 17

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 18

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if TCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TCRX's dividend payments have been increasing.

Dividend Yield vs Market

TScan Therapeutics Dividend Yield vs Market
How does TCRX dividend yield compare to the market?
SegmentDividend Yield
Company (TCRX)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.4%
Analyst forecast (TCRX) (up to 3 years)n/a

Notable Dividend: Unable to evaluate TCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate TCRX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TCRX has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 10:42
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TScan Therapeutics, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Andres MaldonadoH.C. Wainwright & Co.
Christopher HowertonJefferies LLC